Mesoblast Limited: Strong Growth and Strategic Developments

Mesoblast Limited (ASX: MSB) has reported a significant 60% increase in Ryoncil® (remestemcel-L-rknd) sales for the December 2025 quarter, reaching US$35.1 million. This growth continues to strengthen the company’s balance sheet, which is further bolstered by a US$125 million five-year financing facility. Mesoblast is also advancing key clinical trials to broaden Ryoncil®'s use to adults with SR-aGvHD, targeting a market three times the size of the pediatric population. Additionally, the new financing facility has helped reduce the company’s capital costs and provides flexibility for potential strategic partnerships and commercialization initiatives. The company is actively developing further therapies using its proprietary cellular technologies to address other severe inflammatory diseases, including heart failure and chronic pain.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au